Nasogastric tube insertion (NGT) is a common bedside procedure and malpositioned tubes into the tracheobronchial are not uncommon. These can be associated with pulmonary complications. Significantly, pneumothoraces are rare but potential complications that clinicians need to be aware of. We herein report a case of pneumothorax following NGT insertion that necessitated operative management. A 72-year-old male smoker was undergoing rehabilitation after a recent cerebrovascular accident. A NGT change was done and the chest radiograph done to check placement demonstrated the NGT in the right bronchus with the tip in the right pleural space. The NGT was removed and a new one reinserted. A repeat chest radiograph demonstrated a right sided pneumothorax. He underwent radiologically guided chest drain insertion and subsequently required thoracoscopic surgery where a wedge resection of the right lower lobe was performed. The chest drain was removed on day two post operatively and he made an uneventful recovery.
A 51-year-old patient was treated with chemotherapy for two synchronous colon cancers and was diagnosed with Lynch syndrome. The patient also suffered a cardiac arrest and was also diagnosed with a long QT syndrome (LQTS) subsequently. This is the first case of a co-existence of Lynch syndrome and LQTS. Keywords Case HistoryA 51-year-old male presented with a change in his bowel habit and was shown to have iron deficiency anaemia without blood in his stool.There was no family history of cancer, he was not on any medications and had no allergies. Of note was a history of faints. An initial diagnosis of irritable bowel syndrome (IBS) was made and iron supplementation was prescribed. However with no improvement in symptoms, the patient was referred to gastroenterology for colonoscopy and the descending colon biopsy showed an adenocarcinoma. A pre-surgical electrocardiogram (ECG) was normal with a corrected QT (QTc) of 385 (see Figure 1). He underwent a subtotal colectomy and a diagnosis of two synchronous Dukes' stage C (caecum and descending colon) cancers was made. Immunohistochemical (IHC) stains demonstrated a loss of staining for MLH1 and PMS2 in both cancers (see Figures 2a and 2b). Subsequent genetic testing has shown him to be a MLH1 mutation carrier. Following his surgery, the patient received four cycles of adjuvant chemotherapy with oral capecitabine (1,000 mg/m 2 ) and intravenous oxaliplatin (130 mg/m 2 ), called XELOX. XELOX-chemotherapy is delivered as a 3-weekly cycle with oxaliplatin administered on the first day of each cycle and oral capecitabine is taken twice daily for 2 weeks.Our patient tolerated XELOX-chemotherapy well and had no dose reductions. While taking capecitabine tablets as part of the fourth cycle, he unfortunately suffered a cardiac arrest in a public place, but was successfully resuscitated on site. Subsequent cardiac investigations including an adrenaline stress test using the Mayo protocol 1 have led to the diagnosis of LQTS (see Figures 3a and b). Genetic analysis of the most commonly implicated genes, LQT genes 1-5, was negative but this does not exclude the presence of a less common LQT syndrome. One of our patient's children was also found to have a positive adrenaline stress test and has been started on β-blockers. This strengthens the likelihood of an underlying genetic cause for the LQT syndrome. It was thought that the chemotherapy tablet capecitabine and/or the metic domperidome, given over 5 days at the beginning of each cycle at a dose of 20 mg three times per day, led to an unmasking of the thus far undiagnosed LQTS. Subsequently an implantable cardioverterdefibrillator was inserted and adjuvant chemotherapy was stopped.He has undergone genetic counselling for the inherited disorders and continued to attend oncological follow-up. He is now 2 years post the cardiac arrest, clinically well with a performance status of 0, and has no evidence of a cancer associated with HNPCC. Hereditary Non-polyposis Colorectal CancerHNPCC, also known as Lynch syndrome, is a...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.